368 related articles for article (PubMed ID: 15742464)
1. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
Dinarello CA
J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
[TBL] [Abstract][Full Text] [Related]
2. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
3. Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT; Bathon JM
J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
[TBL] [Abstract][Full Text] [Related]
4. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
Ehlers S
J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
[TBL] [Abstract][Full Text] [Related]
5. Problems encountered during anti-tumour necrosis factor therapy.
Desai SB; Furst DE
Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
[TBL] [Abstract][Full Text] [Related]
6. Safety of biologic therapies--an update.
Keystone EC
J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
[TBL] [Abstract][Full Text] [Related]
7. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
8. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
9. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
[TBL] [Abstract][Full Text] [Related]
11. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
Wallis RS
Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.
Harris J; Hope JC; Keane J
J Infect Dis; 2008 Dec; 198(12):1842-50. PubMed ID: 18954258
[TBL] [Abstract][Full Text] [Related]
13. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases.
Botsios C
Autoimmun Rev; 2005 Mar; 4(3):162-70. PubMed ID: 15823502
[TBL] [Abstract][Full Text] [Related]
14. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
[TBL] [Abstract][Full Text] [Related]
15. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
Rigby WF
Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
[TBL] [Abstract][Full Text] [Related]
17. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
Hochberg MC; Lebwohl MG; Plevy SE; Hobbs KF; Yocum DE
Semin Arthritis Rheum; 2005 Jun; 34(6):819-36. PubMed ID: 15942917
[TBL] [Abstract][Full Text] [Related]
18. The yin and yang of tumor necrosis factor inhibitors.
Calabrese L
Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
[TBL] [Abstract][Full Text] [Related]
19. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
Keane J
Rheumatology (Oxford); 2005 Jun; 44(6):714-20. PubMed ID: 15741198
[TBL] [Abstract][Full Text] [Related]
20. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]